Interim 2023/2024 Season Influenza Vaccine Effectiveness in Primary and Secondary Care in the United Kingdom.

Humans Influenza Vaccines / immunology Influenza, Human / prevention & control Adolescent Adult Child Child, Preschool Middle Aged Young Adult United Kingdom Aged Influenza A Virus, H3N2 Subtype / immunology Primary Health Care Male Female Influenza A Virus, H1N1 Subtype / immunology Secondary Care Seasons Vaccine Efficacy Vaccination / statistics & numerical data

effectiveness hospitalisation influenza vaccine

Journal

Influenza and other respiratory viruses

ISSN: 1750-2659

Titre abrégé: Influenza Other Respir Viruses

Pays: England

ID NLM: 101304007

Informations de publication

Date de publication:
May 2024

Historique:

revised: 12 03 2024

received: 28 02 2024

accepted: 13 03 2024

medline: 22 5 2024

pubmed: 22 5 2024

entrez: 22 5 2024

Statut: ppublish

Résumé

We report 2023/2024 season interim influenza vaccine effectiveness for three studies, namely, primary care in Great Britain, hospital settings in Scotland and hospital settings in England. A test negative design was used to estimate vaccine effectiveness. Estimated vaccine effectiveness against all influenzas ranged from 63% (95% confidence interval 46 to 75%) to 65% (41 to 79%) among children aged 2-17, from 36% (20 to 49%) to 55% (43 to 65%) among adults 18-64 and from 40% (29 to 50%) to 55% (32 to 70%) among adults aged 65 and over. During a period of co-circulation of influenza A(H1N1)pdm09 and A(H3N2) in the United Kingdom, evidence for effectiveness of the influenza vaccine in both children and adults was found.

Sections du résumé

BACKGROUND BACKGROUND

We report 2023/2024 season interim influenza vaccine effectiveness for three studies, namely, primary care in Great Britain, hospital settings in Scotland and hospital settings in England.

METHODS METHODS

A test negative design was used to estimate vaccine effectiveness.

RESULTS RESULTS

Estimated vaccine effectiveness against all influenzas ranged from 63% (95% confidence interval 46 to 75%) to 65% (41 to 79%) among children aged 2-17, from 36% (20 to 49%) to 55% (43 to 65%) among adults 18-64 and from 40% (29 to 50%) to 55% (32 to 70%) among adults aged 65 and over.

CONCLUSIONS CONCLUSIONS

During a period of co-circulation of influenza A(H1N1)pdm09 and A(H3N2) in the United Kingdom, evidence for effectiveness of the influenza vaccine in both children and adults was found.

Identifiants

DOI: 10.1111/irv.13284 PMID: 38773753

pubmed: 38773753

doi: 10.1111/irv.13284

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Pagination

e13284

Subventions

Organisme : UK Health Security Agency, Public Health Scotland and Public Health Wales

Informations de copyright

Références

UK Health Security Agency, “The Green Book; Chapter 19: Influenza. UKHSA Gateway Number 2020296,” accessed 15 Feb 2024, https://www.gov.uk/government/publications/influenza‐the‐green‐book‐chapter‐19.

G. Smith, A. McMahon, and A. Strath, “Seasonal Flu Immunisation Programme 2023/24: Confirmation of Adult Cohorts. 18 April 2023,” Letter, The Scottish Government, accessed February 15, 2024, https://www.sehd.scot.nhs.uk/cmo/CMO(2023)05.pdf.

World Health Organization (WHO), “Recommended Composition of Influenza Virus Vaccines for Use in the 2023–2024 Northern Hemisphere Influenza Season,” 24 February 2023, Meeting report, Geneva: WHO, accessed February 6, 2023, https://www.who.int/publications/m/item/recommended‐composition‐of‐influenza‐virus‐vaccines‐for‐use‐in‐the‐2023‐2024‐northern‐hemisphere‐influenza‐season.

Public Health Wales, “Public Health Wales Influenza Surveillance Report: Week 4 2024,” accessed February 6, 2024, https://phw.nhs.wales/topics/immunisation‐and‐vaccines/fluvaccine/weekly‐influenza‐and‐acute‐respiratory‐infection‐report/.

Public Health Scotland, “Viral Respiratory Diseases (Including Influenza and COVID‐19) in Scotland Surveillance Report: 01 February 2024,” accessed February 6, 2024, https://www.publichealthscotland.scot/publications/viral‐respiratory‐diseases‐including‐influenza‐and‐covid‐19‐in‐scotland‐surveillance‐report/viral‐respiratory‐diseases‐including‐influenza‐and‐covid‐19‐in‐scotland‐surveillance‐report‐1‐february‐2024/.

UK Health Security Agency, “National Influenza and COVID‐19 Surveillance Report. Week 5 Report (up to Week 4 2024 Data), 1 February 2024,” accessed February 6, 2024, https://www.gov.uk/government/statistics/national‐flu‐and‐covid‐19‐surveillance‐reports‐2023‐to‐2024‐season.

A. K. Clift, C. A. C. Coupland, R. H. Keogh, et al., “Living Risk Prediction Algorithm (QCOVID) for Risk of Hospital Admission and Mortality from Coronavirus 19 in Adults: National Derivation and Validation Cohort Study,” BMJ 371 (2020): m3731, https://doi.org/10.1136/bmj.m3731.

R. G. Pebody, H. Whitaker, J. Ellis, et al., “End of Season Influenza Vaccine Effectiveness in Primary Care in Adults and Children in the United Kingdom in 2018/19,” Vaccine 38, no. 3 (2020): 489–497, https://doi.org/10.1016/j.vaccine.2019.10.071.

H. Whitaker, K. Hassell, K. Hoschler, et al., “Influenza Vaccination During the 2021/22 Season: A Data‐Linkage Test‐Negative Case‐Control Study of Effectiveness Against Influenza Requiring Emergency Care in England and Serological Analysis of Primary Care Patients,” Vaccine 42 (2024): 1656–1664, https://doi.org/10.1016/j.vaccine.2024.02.006.

E. Kissling, M. Maurel, H. D. Emborg, et al., “Interim 2022/23 Influenza Vaccine Effectiveness: Six European Studies, October 2022 to January 2023,” Eurosurveillance 28, no. 21 (2023): pii=2300116, https://doi.org/10.2807/1560‐7917.ES.2023.28.21.2300116.

Public Health Scotland, “Community Acute Respiratory Infection (CARI) Surveillance in Primary Care,” 2023, https://publichealthscotland.scot/media/23330/cari‐surveillance‐in‐primary‐care‐english‐november2023.pdf.

M. K. Doll, S. M. Pettigrew, J. Ma, and A. Verma, “Effects of Confounding Bias in Coronavirus Disease 2019 (COVID‐19) and Influenza Vaccine Effectiveness Test‐Negative Designs Due to Correlated Influenza and COVID‐19 Vaccination Behaviors,” Clinical Infectious Diseases 75, no. 1 (2022): e564–e571, https://doi.org/10.1093/cid/ciac234.

C. Smolarchuk, C. Ickert, N. Zelyas, J. C. Kwong, and S. A. Buchan, “Early Influenza Vaccine Effectiveness Estimates Using Routinely Collected Data, Alberta, Canada, 2023/24 Season,” Eurosurveillance 29, no. 2 (2024): 2300709, https://doi.org/10.2807/1560‐7917.ES.2024.29.2.2300709.

World Health Organization (WHO), “Recommended Composition of Influenza Virus Vaccines for Use in the 2024 Southern Hemisphere Influenza Season,” 29 September 2023, Meeting report, Geneva: WHO, accessed February 15, 2023, https://www.who.int/publications/m/item/recommended‐composition‐of‐influenza‐virus‐vaccines‐for‐use‐in‐the‐2024‐southern‐hemisphere‐influenza‐season.